Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/

领导和运营中心（LOC）、艾滋病临床试验组（ACTG）；

• 批准号: 10182391
• 负责人: Judith S. Currier
• 金额: $ 18194.26万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-06-24 至 2020-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10182391
• 关键词: AIDS clinical trial group; COVID-19; Centers for Disease Control and Prevention (U.S.); Clinic; Clinical Trials Cooperative Group; Enrollment; HIV; Infection Control; Leadership; Location; Measures; Participant; Patients; Phase; Population; Prevention; Protocols documentation; clinical research site; coronavirus disease; operation; phase III trial; prevention clinical trial

To more safely and efficiently treat COVID-19 participants, we request support to place COVID-19 Isolation PODS at 14 of the ACTG CRSs. The storage company, PODS, has developed stand-alone and CDC compliant units. Installation of a COVID-19 POD at CRS locations will primarily facilitate A5401 but also protocol A5395. These units additionally allow separation between these activities and our HIV patients for both COVID treatment and prevention studies. A5401 will study up to 10 different agents across phase 2 and phase 3 trials. This dedicated space will allow for efficient treatment of a high volume of study participants without comprising infection control measures of the general clinic population.

为了更安全、更高效地治疗新冠肺炎参与者，我们请求支持在ACTG CRSS的14个位置放置新冠肺炎隔离舱。存储公司Pods已经开发了独立的和CDC兼容的单元。 在CRS地点安装新冠肺炎POD将主要促进A5401，但也有助于A5395协议。这些单位还允许将这些活动与我们的艾滋病毒患者分开，用于COVID治疗和预防研究。 A5401将在2期和3期试验中研究多达10种不同的药物。这一专用空间将允许对大量研究参与者进行有效治疗，而不包括普通诊所人口的感染控制措施。